Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).
The most significant data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in France in October 2012, have been summarised in the fifth edition of the Post-ECTRIMS Experts Meeting, held in Madrid in October 2012. This led to the drafting of this review, which has been published in three parts. This third part of the Post-ECTRIMS review presents the findings from the latest studies conducted with disease-modifying treatments, more specifically with glatiramer acetate, laquinimod, ponesimod, BG-12, teriflunomide, daclizumab, natalizumab and secukinumab (AIN457). Likewise, we also address the reasons that justify the search for innovative treatments for multiple sclerosis, with antigen-specific therapy, cell therapy and therapy aimed at promoting remyelination being highlighted among other future therapeutic strategies. Access to new pharmacological agents and the complexity of the therapy of multiple sclerosis in the future will require new design strategies and directions in clinical trials, including the use of surrogate markers, new statistical applications, superiority, inferiority or equivalence clinical trials and adaptable designs.
Fundacion IMABIS, Hospital Universitario Carlos Haya, 29190 Malaga, Espana.
Óscar
Ó
Fernández
Carmen
C
Arnal-García
Rafael
R
Arroyo-González
Lluís
L
Brieva
M Carmen
MC
Calles-Hernández
Bonaventura
B
Casanova-Estruch
Manuel
M
Comabella
Virginia
V
de las Heras
Juan A
JA
García-Merino
Miguel A
MA
Hernández-Pérez
Guillermo
G
Izquierdo
Elisabet
E
Matas
José E
JE
Meca-Lallana
María del Mar
Mdel M
Mendibe-Bilbao
Delicias
D
Muñoz-García
Javier
J
Olascoaga
Celia
C
Oreja-Guevara
José M
JM
Prieto
Lluís
L
Ramió-Torrentà
Alfredo
A
Rodríguez-Antigüedad
Albert
A
Saiz
Nieves
N
Téllez
Luisa M
LM
Villar
Mar
M
Tintoré
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D015195:Drug Design; D005060:Europe; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000517:prevention & control; D045164:Mesenchymal Stem Cell Transplantation; D058990:Molecular Targeted Therapy; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D060735:Pharmacovigilance; D035703:Therapies, Investigational
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents